From the Journals

fMRI might help differentiate MDD and bipolar disorder


 

FROM PSYCHIATRY RESEARCH: NEUROIMAGING

The hippocampal functional connectivity (FC) found in patients with major depressive disorder is different from the FC found in patients with bipolar disorder, an analysis of functional MRI data shows.

These findings may assist investigators in attempting to distinguish mood disorders by using fMRI data,” Ahmed Ameen Fateh and his associates wrote in Psychiatry Research: Neuroimaging.

Mr. Fateh and his associates recruited 29 participants with depression and 30 with bipolar disorder, from a mental health center of Chengdu, Sichuan, China. An additional 30 healthy controls were recruited through advertisements, reported Mr. Fateh, a doctoral student at the University of Electronic Science and Technology of China, Chengdu.

Using one-way analysis of variance, the investigators looked at possible differences in the participants’ hippocampal FC. The results showed that some regions exhibited significant differences in the hippocampal FC among the patients with major depression and bipolar disorder.

If their results could be replicated, the researchers wrote, “such differences may yield future trends towards improving the clinical differentiation between these two types of depression with significant therapeutic and prognostic implications.”

SOURCE: Fateh AA et al. Psychiatry Res Neuroimaging. 2019 Jan 12. doi: 10.1016/j.pscychresns.2019.01.004.

Recommended Reading

For most veterans with PTSD, helping others is a lifeline
Federal Practitioner
Low and high BMI tied to higher postpartum depression risk
Federal Practitioner
Interacting with horses helps veterans with PTSD; Identical twin battles anorexia
Federal Practitioner
Identifying and stopping a likely mass shooter: A case study
Federal Practitioner
Comorbid TBI & PTSD raise the risk for sleep disturbances, pain
Federal Practitioner
Overemphasizing Communities in the National Strategy for Preventing Veteran Suicide Could Undercut VA Successes
Federal Practitioner
FDA panels back intranasal esketamine for refractory depression
Federal Practitioner
Suicide: Igor Galynker
Federal Practitioner
ICU admissions raise chronic condition risk
Federal Practitioner
FDA approves intranasal esketamine for refractory major depressive disorder
Federal Practitioner